Skip to content
Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc.

RYTM

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company specializing in precision medicines for rare neuroendocrine diseases.

Market cap
$7.28B+30.3%
Revenue$217.2M+58.7%
Net income-$202.7M-20.2%
EPS (diluted)-$3.13-11.4%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$67.7M
EPS estimate-$0.82

Financials

Q1 2026

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%

Valuation & ratios

Valuation

See full
Market cap$7.28B+30.3%
Enterprise value$7.33B+30.1%
P/S33.5×-2.7×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Segments

By segment

See full
Single reportable segment$60.1M+83.8%

By product

See full
License revenue-+100%

Competitors

Profile

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company specializing in precision medicines for rare neuroendocrine diseases. The company focuses on developing and commercializing melanocortin-4 receptor (MC4R) agonists to treat hyperphagia and severe obesity caused by genetic variants or acquired injuries that impair the MC4R pathway.

Competitive position

A first-mover in the MC4R pathway space with the first-ever approved therapy for Bardet-Biedl syndrome and monogenic obesity.

GeographiesUnited States, European Union, United Kingdom, Canada, Japan
Customer segmentsRare disease patients, Pediatric patients, Endocrinologists
Business modelR&D intensive, Direct-to-market pharmaceutical sales
SuppliersGenetic sequencing providers, Contract manufacturing organizations, Clinical research organizations
CustomersSpecialty distributors, Government healthcare payers, Private insurance companies, Patients with rare genetic obesity
Listed2017
Employees226.0
CEODavid Meeker
FilingsSEC EDGAR

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s market cap?
Rhythm Pharmaceuticals, Inc. (RYTM) has a market capitalization of $7.3B and trades on NASDAQ.
What is Rhythm Pharmaceuticals, Inc.'s revenue and profitability?
Rhythm Pharmaceuticals, Inc. generated $217.2M in trailing twelve-month revenue with a net loss of $202.7M, representing a net margin of -93.3%. Gross margin stands at 89.4%. These figures are based on the Q1 2026 filing.
Who are Rhythm Pharmaceuticals, Inc.'s competitors?
Rhythm Pharmaceuticals, Inc.'s key competitors include Eli Lilly, Palatin Technologies, Inc., Viking Therapeutics, Inc, and others. These companies compete in similar markets and product categories.
Who does Rhythm Pharmaceuticals, Inc. partner with?
Rhythm Pharmaceuticals, Inc.'s notable partners include U.S. Food and Drug Administration, European Commission.
Where is Rhythm Pharmaceuticals, Inc. headquartered?
Rhythm Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 226 people. It has been publicly traded since 2017.